Please assess the completion status of the following clinical trial:

Trial Title: Augmentation Trial of Prazosin for Post-Traumatic Stress Disorder (PTSD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Age \>18 years;~* Clear evidence of exposure to one or more war zone trauma events sufficient to satisfy DSM-IV criterion A1 for diagnosis of PTSD;~* DSM-IV diagnosis of PTSD derived from the CAPS; CAPS total score \>50;~* CAPS Recurrent Distressing Dreams item score \>5 (of maximum score of 8);~* stable dose of non-exclusionary medications and psychotherapeutic treatment for at least 4 weeks prior to randomization;~* good general medical health.~* Female participants must agree to use a reliable form of birth control during the study.~Exclusion Criteria~* Psychiatric/Behavioral - meets DSM-IV criteria for current schizophrenia, schizoaffective disorder, psychotic disorder, delirium, or any DSM-IV cognitive disorder; substance dependence disorder within 3 months or any current substance dependence; current cocaine or stimulant abuse; severe psychiatric instability or severe situational life crises, including evidence of being actively suicidal or homicidal, or any behavior which poses an immediate danger to patient or others.~* Medical - acute or unstable chronic medical illness, including unstable angina, recent myocardial infarction (within 6 months), congestive heart failure, preexisting hypotension or orthostatic hypotension, chronic renal or hepatic failure, pancreatitis, Meniere's disease, benign positional vertigo; narcolepsy, or diagnosed sleep apnea; allergy or previous adverse reaction to prazosin or other alpha-1 antagonist.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- prazosin hydrochloride (Type: ACTIVE_COMPARATOR): prazosin Pfizer Minipress~oral capsules~Subject will be titrated up to the optimum tolerated dose based on the Dosing Algorithm. Males and females will be titrated differently with females titrated slower and to a lower maximum daily dose.
- placebo (Type: PLACEBO_COMPARATOR): placebo~oral capsules~Subject will be titrated up to the optimum tolerated dose based on the Dosing Algorithm. Males and females will be titrated differently with females titrated slower and to a lower maximum daily dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).